anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a reagent for causing a targeting effect of marrow mesenchymal stem cells on myocardial infarction focus, and its preparation method. The reagent is composed of a culture medium for causing a targeting effect of marrow mesenchymal stem cells on myocardial infarction focus, and marrow mesenchymal stem cells. The culture medium comprises solutes and a solvent. The solutes comprises the following seven components of 4.0 to 5.0 g/L of glucose, 0.11 to 0.19 g/L of sodium carbonate, 0.584 to 0.702 g/L of L-glutamine solution, 100 to 130 ml/L of dimethyl sulfoxide, 50 to 67 g/L of transferring, 5 to 6.6 g/L of insulin, and 0.01 to 0.05 g/L of basic fibroblast growth factor, wherein a concentration of each one of the components is a final concentration. The solvent is injection water. The reagent can cause a targeting effect of marrow mesenchymal stem cells on myocardial infarction focus and solves the problem that at present, through an intracoronary injection way, a small number of cells are leaved.
Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
Disclosed are polypeptide compounds using PD-1 receptors as targets. The polypeptide compounds comprise a compound 1, a compound 2, a compound 3, a compound 4 and a compound 5. The amino acid sequences of the compounds 1-5 are as shown in SEQ ID NOs: 1-5. Further disclosed is a method for preparing polypeptide compounds using PD-1 receptors as targets, comprising the following processes: sequentially coupling the amino acids of the compounds 1-5 onto a solid-phase resin according to peptide sequences by using a solid-phase synthesis method; and performing cleavage by a cutting reagent, freeze-drying, and preparing and purifying to obtain a target compound. Further disclosed is a use of polypeptide compounds using PD-1 receptors as targets in the preparation of analgesic drugs. The small molecule polypeptides of the present invention, the compounds 1-5, can bind to PD-1, and have a significant inhibitory effect on both inflammatory pain and visceral pain by intrathecal administration; and the synthesis is simple and the purification is easy, facilitating large-scale synthesis.
The chromium in this agent is present as the dianionic chromate ion in which form it appears to bind to the red blood cell in two steps, initially by a rapid but reversible attachment to the cell membrane followed by a slower nearly irreversible binding to intracellular hemoglobin and reduction to the anionic state. It has been suggested that the slow rate of uptake is dependent on the rate at which chromate can penetrate the cell membrane. Binding is maintained until the red blood cells are sequestered by the spleen or until elution of the chromium occurs into the plasma. The chromium is then readily excreted mainly in the urine. Once liberated by elution or erythrocyte senescence, chromium 51 is not available for relabeling of red cells.

In normal individuals the erythrocyte survival half-time T ½ as measured by the chromium 51 "random labeling" technique, generally ranges between 25 and 35 days. This apparent short survival time, when compared to the 120 day life span of the red blood cells, is due to the elution of chromium from the cells and to cell damage that probably occurs during the process of withdrawing them from the body and labeling. Subnormal T ½ may be indicative of blood toss, sequestration of red blood cells by the spleen, or shortened cell viability, as occurs In hemolytic anemia
Previous studies at the NIH have demonstrated that in over 90% of cases of Wegener's granulomatosis (WG) and other systemic necrotizing vasculitides, glucocorticoid (GC) and daily low dose cyclophosphamide (CP) therapy has resulted in marked improvement and even remission. However, such therapy has been associated with about 50% relapses, 10% resistance to initial treatment and significant toxicity in almost all patients. Consequently, we have attempted to identify alternative therapies for the systemic vasculitides that would be less toxic then daily CP. An NIH study of the efficacy of intermittent high dose intravenous CP and daily GC (Protocol #88-I-56) revealed that 79% of 14 patients with WG either failed to respond to treatment, did not sustain improvement or could not tolerate continued treatment during a period of approximately two years. In another study (Protocol #89-I-18), we evaluated treatment with GC and weekly oral doses of methotrexate (MTX) in 15 patients with Takayasu's arteritis, in whom disease previously failed to be controlled with GC, GC + CP, or in whom remission with such treatment was followed by relapse. Fifty-three percent (8/15) of patients previously dependent on GC were able to achieve remission and discontinue GC therapy. Five of seven patients who remained on GC were in remission and receiving at least 50% less GC than prior to MTX therapy. Only three patients had progressive disease. The mean follow-up period was 20 months. We have also recently analyzed our results for MTX + GC therapy and 29 patients with WG. Seventy-six percent of patients had marked improvement and 69% achieved remission. Seventy-two percent of those in remission have not required GC therapy for a mean period 10 months. We conclude that weekly low dose MTX therapy is a feasible alternative to CP in the treatment of systemic vasculitis. Judgement of the ultimate value of such therapy should be deferred until a greater number of patients have been studied over a longer period of time.
The invention is related to peptide constructs,  i.e. , polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P 1 -x-P 2 , where P 2  is a peptide associated with an infectious agent and P 1  is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent. Dyes, radioisotopes, or therapeutic agents conjugated with the dendritic cells can be used for localization of the immune target and/or prophylactic or therapeutic treatment of the disease.
The invention relates to the fields of food, health food and traditional Chinese medicine, in particular to a traditional Chinese medicine composition and a preparation with the function of enhancing immunity. The feed is prepared from the following raw materials in parts by weight: 30-80 parts of chicory and 20-70 parts of medicinal cyathula root. The chicory and the radix cyathulae are used together, and the chicory has the effects of invigorating stomach, promoting digestion, promoting urination and reducing swelling; chuan xi Yu has combining action of inducing diuresis and treating stranguria and tonifying liver and kidney. Has the effects of soothing liver, regulating stomach, promoting diuresis and purging turbid. It has no incompatibility and mild property. Strengthen the body resistance and consolidate the constitution, remove dampness and eliminate pathogenic factors, take the root and symptoms into consideration and bring out the best in each other. Meanwhile, chicory polysaccharide, cyathula root polysaccharide and a plurality of active polysaccharides have complementary advantages and synergistic effect, and can effectively play a health-care function of enhancing immunity.
<P>PROBLEM TO BE SOLVED: To obtain the status of past and future medical examination schedule related to a patient easily and clearly.  <P>SOLUTION: A display bar 75 for indicating a medical examination schedule period is displayed on a medical examination schedule display section 74 on a medical examination schedule screen 70 for each item 73 of each medical examination. Additionally, a present time display bar 76 for indicating a present time is also displayed, and the display formats of the past and future display bars 75 are made different with the present time display bar 76 as a boundary. The display formats of the schedule period display bar are made different between a medical examination schedule having been executed normally, a medical examination schedule 75c resulted in an error, and a medical examination schedule 75b that has not been executed in the past medical examination schedule. Also for future medical examination schedules, the display bar 75 is normally displayed with a thick bar, while it is displayed with a thin bar 75a for a medical examination schedule that is not notified to a patient. Additionally, when the start and end of a medical examination act are not decided, edges are displayed with tapered bars 75d, 75e.  <P>COPYRIGHT: (C)2007,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a food composition having no possibility of side effect, effective and highly safe and having ameliorating effect of gout and hyperuricemia.  <P>SOLUTION: This food composition has as the active ingredient the plant dry material or the extract of the Hamamelis virginiana or the Limonium wrightii O. Kuntze. The edible plants each have an inhibition activity of xanthine oxidase becoming a cause of gout and low toxicity since being derived from natural products. It is a new finding that the dry products and the extracts of the edible plants each have the inhibition activity of xanthine oxidase since the fact has been entirely conventionally unknown. The edible plants each have the superior inhibition activity of xanthine oxidase and are usable as a food for preventing and ameliorating gout and hyperuricemia.  <P>COPYRIGHT: (C)2003,JPO
The objective of this study is to investigate whether acute changes in heart rate variability following a single session of repetitive transcranial magnetic stimulation (rTMS) can predict the response to a 30-session course of rTMS in patients with major depressive disorder (MDD) with good sensitivity and specificity. Patients who are prescribed rTMS to treat an episode of MDD at one of the nine participating centres will be invited to participate in the study. The protocol includes one inclusion visit and seven evaluation visits before, during, and after the course of rTMS. The rTMS course will last for six weeks, comprising of 30 sessions with five sessions per week. Prior to the start of the rTMS course, the patient will have to fill in a number of questionnaires. Before the first session, heart rate variability will be assessed by recording the RR interval at rest using a heart rate belt on the armchair stimulation. A second RR interval recording will be taken immediately after the first rTMS session. Patients will answer questionnaires weekly and after the final rTMS session to track the progression of depressive symptoms.
OBJECTIVE: Ischemia/reperfusion can impair microcirculatory blood flow. It remains unknown whether colloids are superior to crystalloids for restoration of microcirculatory blood flow during ischemia/reperfusion injury. We tested the hypothesis that goal-directed colloid - compared to crystalloid - therapy improves small intestinal, renal, and hepatic microcirculatory blood flow in pigs with ischemia/reperfusion injury.
METHODS: This was a randomized trial in 32 pigs. We induced ischemia/reperfusion by supra-celiac aortic-cross-clamping. Pigs were randomized to receive either goal-directed isooncotic hydroxyethyl-starch colloid or balanced isotonic crystalloid therapy. Microcirculatory blood flow was measured using Laser-Speckle-Contrast-Imaging. The primary outcome was small intestinal, renal, and hepatic microcirculatory blood flow 4.5 h after ischemia/reperfusion. Secondary outcomes included small intestinal, renal, and hepatic histopathological damage, macrohemodynamic and metabolic variables, as well as specific biomarkers of tissue injury, renal, and hepatic function and injury, and endothelial barrier function.
RESULTS: Small intestinal microcirculatory blood flow was higher in pigs assigned to isooncotic hydroxyethyl-starch colloid therapy than in pigs assigned to balanced isotonic crystalloid therapy (768.7 (677.2-860.1) vs. 595.6 (496.3-694.8) arbitrary units, p = .007). There were no important differences in renal (509.7 (427.2-592.1) vs. 442.1 (361.2-523.0) arbitrary units, p = .286) and hepatic (604.7 (507.7-701.8) vs. 548.7 (444.0-653.3) arbitrary units, p = .376) microcirculatory blood flow between groups. Pigs assigned to colloid - compared to crystalloid - therapy also had less small intestinal, but not renal and hepatic, histopathological damage.
CONCLUSIONS: Goal-directed isooncotic hydroxyethyl-starch colloid - compared to balanced isotonic crystalloid - therapy improved small intestinal, but not renal and hepatic, microcirculatory blood flow in pigs with ischemia/reperfusion injury. Whether colloid therapy improves small intestinal microcirculatory blood flow in patients with ischemia/reperfusion needs to be investigated in clinical trials.
Concomitant direct oral anticoagulants (DOACs) and tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (anti-VEGF TKI) have been associated with a higher risk of bleeding. Nevertheless, concomitant administration seems frequent in clinical practice in patients with cancer-associated thrombosis and appears to be safe according to the retrospective study by Boileve A. et al. But the risk of an additional pharmacokinetic interaction between anti-VEGF TKI and DOACs must be considered, in case of P-glycoprotein (P-gp) inhibition by the TKI. We describe a case report with a major bleeding event in a renal metastatic cancer patient treated with cabozantinib and rivaroxaban. This case highlights the difficult therapeutic decision in a complex patient with cancer-associated thrombosis, who refused the anticoagulant subcutaneous route. Accumulation of bleeding risk factors (genito-urinary tumor localization) was additive to several pharmacodynamic interactions (acetylsalicylic acid, venlafaxine) and a potential pharmacokinetic interaction between cabozantinib and rivaroxaban. Indeed, cabozantinib-related P-glycoprotein inhibition could have led to a supratherapeutic level of rivaroxaban, contributing partly to the bleeding event. Before combining an anti-VEGF TKI and DOACs, a multidisciplinary pretherapeutic assessment seems crucial to evaluate the patient's bleeding risk factors, pharmacodynamic interactions, and the risk of pharmacokinetic interactions mediated by P-gp.
OBJECTIVE: Prediction of fetal growth restriction (FGR) and small of gestational age (SGA) infants by using various ultrasound cardiac parameters in a logistic regression model.
METHODS: In this retrospective study we obtained standardized ultrasound images of 357 fetuses between the 20th and 39th week of gestation, 99 of these fetuses were between the 3rd and 10th growth percentile, 61 smaller than 3rd percentile and 197- appropriate for gestational age over the 10th percentile (control group). Several cardiac parameters were studied. The cardiothoracic ratio and sphericity of the ventricles was calculated. A binary logistic regression model was developed for prediction of growth restriction using the cardiac and biometric parameters.
RESULTS: There were noticeable differences between the control and study group in the sphericity of the right ventricle (p = 0.000), left and right longitudinal ventricle length (pright = 0.000, pleft = 0.000), left ventricle transverse length (p = 0.000), heart diameter (p = 0.002), heart circumference (p = 0.000), heart area (p = 0.000), and thoracic diameter limited by the ribs (p = 0.002). There was no difference of the cardiothoracic ratio between groups. The logistic regression model achieved a prediction rate of 79.4 % with a sensitivity of 74.5 % and specificity of 83.2 %.
CONCLUSION: The heart of growth restricted infants is characterized by a more globular right ventricle, shorter ventricle length and smaller thorax diameter. These parameters could improve prediction of FGR and SGA.
To evaluate the tissue response, intraoral impressions and X-ray will be taking from each patient before extraction and three months after. Also, Cone-beam computed tomography (CBCT) will be taking to measure the bone growth at base line and three months after surgery is done. For measurement, each socket will be vertically divided into 3 equal areas: coronal, middle, and apical. Regenerated bone density will be assessed in each area, in both control and intervention groups.

Data then can be analyzed using SPSS ver. 11 (SPSS Inc., Chicago,USA). P-values less than 0.05 were considered as significant.
Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
A method  and  apparatus  for  tracking  with  a central  monitoring  system  status and result information associated with a plurality of test cards.   Each  of  the test  cards  is anonymously associated with a patient such that  the patient's identity is  unknown  to  the  central monitoring   system.   A  first  set  of  unique  personal identification numbers (PINs)  is  stored  in  a  personal identification  number  database in the central monitoring system, and a first digital signal representative of  PINs from  the  first  set of unique PINs is provided to a test kit assembler.  A second digital signal is received in the central  monitoring  system   from the test kit assembler. The second digital signal is representative of  test  kits actually  assembled.   Each  of  the  test  kits  actually assembled includes a test card having one  of  the  unique PINs   from  the  first  set  of  unique  PINs  associated therewith.  The first set of unique  PINs  is  tracked  by updating  the  personal  identification number database in response to the second digital signal.   A  third  digital signal is provided from the central monitoring system to a test lab. The third digital signal is representative of a second  set  of unique PINs and is provided by the central monitoring  system  in  response  to  the  second  digital signal. A fourth digital  signal  is  received  in the central monitoring system from the test lab.   The  fourth digital signal is representative of test cards received at the test lab  from  patients.   Each  of  the  test  cards received   at  the  test  lab  is  known  to  the  central monitoring system only by one of the unique PINs from  the first  set  of unique PINs, and the identities of patients associated with the test cards received at  the  test  lab are anonymous to the central monitoring system.  The first set of unique PINs is further  tracked  from  the  central monitoring  system by updating the personal identification number database and a test results database in response to the fourth digital signal.
BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is a highly prevalent genetic disorder resulting in markedly elevated LDL cholesterol levels and premature coronary artery disease. FH underdiagnosis and undertreatment require novel detection methods. This study evaluated the effectiveness of using an LDL cholesterol cut-off ≥99.5th percentile (sex- and age-adjusted) to identify clinical and genetic FH, and investigated underutilization of genetic testing and undertreatment in FH patients.
METHODS: Individuals with at least one prior LDL cholesterol level ≥99.5th percentile were selected from a laboratory database containing lipid profiles of 590,067 individuals. The study comprised three phases: biochemical validation of hypercholesterolemia, clinical identification of FH, and genetic determination of FH.
RESULTS: Of 5614 selected subjects, 2088 underwent lipid profile reassessment, of whom 1103 completed the questionnaire (mean age 64.2 ± 12.7 years, 48% male). In these 1103 subjects, mean LDL cholesterol was 4.0 ± 1.4 mmol/l and 722 (65%) received lipid-lowering therapy. FH clinical diagnostic criteria were met by 282 (26%) individuals, of whom 85% had not received guideline-recommended genetic testing and 97% failed to attain LDL cholesterol targets. Of 459 individuals consenting to genetic validation, 13% carried an FH-causing variant, which increased to 19% in clinically diagnosed FH patients.
CONCLUSIONS: The identification of a substantial number of previously undiagnosed and un(der)treated clinical and genetic FH patients within a central laboratory database highlights the feasibility and clinical potential of this targeted screening strategy; both in identifying new FH patients and in improving treatment in this high-risk population.
In an echocardiogram analysis method, a diagnostic code is received or generated for an echocardiogram comprising a set of echocardiogram loops. A plurality of different subsets are selected from the echocardiogram. Each subset consists of one or more echocardiogram loops of the set of echocardiogram loops. For each subset, a confidence score indicating relevance of the subset to the diagnostic code is determined using an artificial intelligence (AI) engine operating on the subset, where the AI engine is trained on historical echocardiograms labeled with diagnostic codes. A relevant group of echocardiogram loops is identified based on the determined confidence scores for the respective subsets indicating relevance of the respective subsets to the diagnostic code. An echocardiogram reading user interface is presented, including displaying the diagnostic code associated with the echocardiogram loops of the relevant group of echocardiogram loops.
We will host two world cafe conversations. The first (n = 20) will be specifically or black transgender and gender diverse adults (18+), who are HIV-negative, and have indications for PrEP. The second (n = 20) will be open to transgender and gender diverse adults, who are HIV-negative, and have indication for PrEP.
A macadamia nut crisp pastry and a production method thereof relate to snack food and a production method thereof. The macadamia nut crisp pastry is characterized by the production method which comprises the processes of preparing macadamia nut powder and producing the crisp pastry, wherein the process of preparing macadamia nut powder comprises the step of grinding materials into powder and the process of producing the crisp pastry comprises the steps of stirring and forming. The obtained macadamia nut crisp pastry is snack food with the macadamia nuts as the raw materials and a few condiments as the auxiliary materials. The product has milk white appearance like the crisp pastry and retains the nutrients and flavors of the macadamia nuts. The crispy pastry has crispy and exquisite tissues, without nutlet granules and impurities. With fragrant, sweet and agreeable flavor and full macadamia nut aroma, the macadamia nut crisp pastry is snack food with the effect of health care.